Kantoff PW - Search Results

1

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Smith MR, et al. Among authors: kantoff pw. Cancer. 2004 Oct 1;101(7):1569-74. doi: 10.1002/cncr.20493. Cancer. 2004. PMID: 15468186 Free article. Clinical Trial.

2

Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.

Smith MR, Kantoff PW. Smith MR, et al. Among authors: kantoff pw. Semin Oncol. 1995 Dec;22(6):625-32. Semin Oncol. 1995. PMID: 8539637 Review.

3

The prostate specific antigen. Its use as a tumor marker for prostate cancer.

Kantoff PW, Talcott JA. Kantoff PW, et al. Hematol Oncol Clin North Am. 1994 Jun;8(3):555-72. Hematol Oncol Clin North Am. 1994. PMID: 8707772 Review.

4

Cancer and Leukemia Group B trials for advanced prostate cancer.

Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Small EJ, et al. Among authors: kantoff pw. Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31. Semin Oncol. 1996. PMID: 8996582 Review.

5

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.

Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff P. Brufsky A, et al. Urology. 1997 Jun;49(6):913-20. doi: 10.1016/s0090-4295(97)00091-5. Urology. 1997. PMID: 9187700 Clinical Trial.

6

Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy.

Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, Richie JP, Kantoff PW. Talcott JA, et al. Among authors: kantoff pw. J Natl Cancer Inst. 1997 Aug 6;89(15):1117-23. doi: 10.1093/jnci/89.15.1117. J Natl Cancer Inst. 1997. PMID: 9262249 Clinical Trial.

7

Management of hormone refractory prostate cancer: current standards and future prospects.

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.

8

Prognostic indicators in hormone refractory prostate cancer.

George DJ, Kantoff PW. George DJ, et al. Among authors: kantoff pw. Urol Clin North Am. 1999 May;26(2):303-10, viii. doi: 10.1016/s0094-0143(05)70070-7. Urol Clin North Am. 1999. PMID: 10361553 Review.

9

A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.

Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. Cancer. 1999 Oct 1;86(7):1329-34. doi: 10.1002/(sici)1097-0142(19991001)86:7<1329::aid-cncr31>3.0.co;2-r. Cancer. 1999. PMID: 10506721 Clinical Trial.

10

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664. J Clin Oncol. 1999. PMID: 10550165 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

481 results

Search Page

Filters